“Doc, should I accept this offer or not?”
Robert M. Merion – 19 November 2004
Cardiac morbidity and mortality related to orthotopic liver transplantation
George Therapondos, Andrew D. Flapan, John N. Plevris, Peter C. Hayes – 19 November 2004 – This article briefly discusses the cardiac status of liver transplant recipients and their preoperative cardiac evaluation. It describes in detail perioperative and early and late postoperative complications as well as the cardiac problems associated with immunosuppression. The preoperative cardiovascular status of patients is important in determining how they cope with the stresses imposed by liver transplantation.
Binding of bilirubin and bromosulphthalein to albumin: Implications for understanding the pathophysiology of liver failure and its management
Christian Steiner, Sambit Sen, Jan Stange, Roger Williams, Rajiv Jalan – 19 November 2004 – The binding/transporting functions of albumin provide the rationale for using albumin dialysis (e.g., molecular adsorbents recirculating system [MARS]) in liver failure. This study investigates these properties in vitro, validating the findings in vivo. In vitro bromosulphthalein (BSP) and bilirubin‐spiked plasma were dialyzed against albumin and sampled.
Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: A decision analysis
Manish G. Amin, Michael P. Wolf, John A. TenBrook, Richard B. Freeman, Steve J. Cheng, Daniel S. Pratt, John B. Wong – 19 November 2004 – Expanded criteria donor (ECD) liver grafts have a higher likelihood of primary graft failure (PGF) compared with standard criteria donor (SCD) grafts. Given a choice between an available ECD graft versus waiting for an SCD graft that may not always become available, what should liver transplant candidates do? The study's aim was to estimate 1‐year survival comparing immediate ECD liver grafting with waiting for an SCD organ.
Retransplantation for hepatitis C: What do we really know?
James R. Burton, Hugo R. Rosen – 19 November 2004
Analysis of a successful HCV‐specific CD8+ T cell response in patients with recurrent HCV‐infection after orthotopic liver transplantation
Norbert Hubert Gruener, Maria‐Christina Jung, Axel Ulsenheimer, Joern Tilman Gerlach, Reinhart Zachoval, Helmut Michael Diepolder, Gustavo Baretton, Rolf Schauer, Gerd Rudolf Pape, Carl Albrecht Schirren – 19 November 2004 – Virus‐specific CD8+ T cells play a major role in antiviral immune defenses; their significance in the transplant setting, however, is unclear.
Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C
Mitsugi Shimoda, Rafik M. Ghobrial, Ian C. Carmody, Dean M. Anselmo, Douglas G. Farmer, Hasan Yersiz, Pauline Chen, Sherfield Dawson, Francisco Durazo, Steve Han, Leonard I. Goldstein, Sammy Saab, Jonathan Hiatt, Ronald W. Busuttil – 19 November 2004 – The efficacy of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is not well defined. This study examines the variables that may determine the outcome of OLT for HCC in HCV patients. From 1990 to 1999, 463 OLTs were performed for HCV cirrhosis.
The transplanted liver graft is capable of clearing asymmetric dimethylarginine
Michiel P.C. Siroen, Michiel C. Warlé, Tom Teerlink, Robert J. Nijveldt, Ernst J. Kuipers, Herold J. Metselaar, Hugo W. Tilanus, Dirk J. Kuik, Joost R.M. van der Sijp, Sybren Meijer, Ben van der Hoven, Paul A.M. van Leeuwen – 19 November 2004 – Asymmetric dimethylarginine (ADMA) has been recognized as an endogenous inhibitor of the arginine–nitric oxide (NO) pathway. Its concentration is tightly regulated by urinary excretion and degradation by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which is highly expressed in the liver.
Combined orthotopic heart and liver transplantation: The need for exception status listing1
Paige M. Porrett, Shashank S. Desai, Kathleen J. Timmins, Carol R. Twomey, Seema S. Sonnad, Kim M. Olthoff – 19 November 2004 – Through May 2004, 33 combined orthotopic heart‐liver transplants (OHT/OLT) have been performed nationwide. No published data exist to date regarding outcomes of patients awaiting such transplants, although progression of two organ disease processes may contribute to premature death for waiting patients.
Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection
Guy W. Neff, Christopher B. O'Brien, Jose Nery, Norah J. Shire, Seigo Nishida, Julia delaGarza, Marzia Montalbano, Kamran Safdar, Phillip Ruiz, Eric Rideman, Jose A. Gascon, Andreas G. Tzakis, Juan Madariaga, Steven M. Rudich – 19 November 2004 – Hepatitis C virus (HCV) is becoming the most common indication for liver retransplantation (ReLTx). This study was a retrospective review of the medical records of liver transplant patients at our institution to determine factors that would identify the best candidates for ReLTx resulting from allograft failure because of HCV recurrence.